| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 19403572
[patent_doc_number] => 20240287083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => SOLUTION REFLUX PROCESS FOR MAKING SUBSTITUTED IMIDAZO PYRAZOLES
[patent_app_type] => utility
[patent_app_number] => 18/624178
[patent_app_country] => US
[patent_app_date] => 2024-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10968
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624178
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/624178 | Process for preparing substituted imidazo[4,5-c]pyrazoles | Apr 1, 2024 | Issued |
Array
(
[id] => 20578420
[patent_doc_number] => 12570662
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-10
[patent_title] => Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases
[patent_app_type] => utility
[patent_app_number] => 18/623738
[patent_app_country] => US
[patent_app_date] => 2024-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62815
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623738
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/623738 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | Mar 31, 2024 | Issued |
Array
(
[id] => 19479390
[patent_doc_number] => 20240327432
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => THIOPHENE-PHENOTHIAZINE COMPOUNDS AND SYNTHESIS METHOD THEREOF, AS WELL AS APPLICATION THEREOF IN PREPARATION OF PHOTOTHERAPY MEDICINES
[patent_app_type] => utility
[patent_app_number] => 18/623007
[patent_app_country] => US
[patent_app_date] => 2024-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6532
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 199
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623007
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/623007 | THIOPHENE-PHENOTHIAZINE COMPOUNDS AND SYNTHESIS METHOD THEREOF, AS WELL AS APPLICATION THEREOF IN PREPARATION OF PHOTOTHERAPY MEDICINES | Mar 30, 2024 | Pending |
Array
(
[id] => 20277538
[patent_doc_number] => 20250302780
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-02
[patent_title] => METHOD OF TREATING PREMATURE EJACULATION IN HUMAN MALES WITHOUT SYMPTOMS OF BENIGN PROSTATIC HYPERTROPHY (BPH) USING TAMSULOSIN 0.2MG QOD WHICH DELAYS EJACULATION BY REDUCING THE RATE OF SECRETION AND TRANSPORT BY SEMINAL VESICLES AND PROSTATE IN THE GENITOURINARY TRACT
[patent_app_type] => utility
[patent_app_number] => 18/621112
[patent_app_country] => US
[patent_app_date] => 2024-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621112
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/621112 | METHOD OF TREATING PREMATURE EJACULATION IN HUMAN MALES WITHOUT SYMPTOMS OF BENIGN PROSTATIC HYPERTROPHY (BPH) USING TAMSULOSIN 0.2MG QOD WHICH DELAYS EJACULATION BY REDUCING THE RATE OF SECRETION AND TRANSPORT BY SEMINAL VESICLES AND PROSTATE IN THE GENITOURINARY TRACT | Mar 28, 2024 | Pending |
Array
(
[id] => 20433249
[patent_doc_number] => 12503474
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-23
[patent_title] => Substituted pyrrolo[1,2-b]pyridazines as anthelmintics
[patent_app_type] => utility
[patent_app_number] => 18/622428
[patent_app_country] => US
[patent_app_date] => 2024-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39515
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18622428
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/622428 | Substituted pyrrolo[1,2-b]pyridazines as anthelmintics | Mar 28, 2024 | Issued |
Array
(
[id] => 20527262
[patent_doc_number] => 12545686
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-10
[patent_title] => Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine as EGFR inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/614458
[patent_app_country] => US
[patent_app_date] => 2024-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 11324
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18614458
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/614458 | Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine as EGFR inhibitors | Mar 21, 2024 | Issued |
Array
(
[id] => 19528116
[patent_doc_number] => 20240352018
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG
[patent_app_type] => utility
[patent_app_number] => 18/441757
[patent_app_country] => US
[patent_app_date] => 2024-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25026
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441757
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/441757 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | Feb 13, 2024 | Issued |
Array
(
[id] => 19360761
[patent_doc_number] => 20240262795
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3
[patent_app_type] => utility
[patent_app_number] => 18/440293
[patent_app_country] => US
[patent_app_date] => 2024-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440293
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/440293 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Feb 12, 2024 | Pending |
Array
(
[id] => 19512045
[patent_doc_number] => 20240343731
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION
[patent_app_type] => utility
[patent_app_number] => 18/437153
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45853
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437153
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/437153 | CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION | Feb 7, 2024 | Abandoned |
Array
(
[id] => 19638056
[patent_doc_number] => 12168656
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-12-17
[patent_title] => Process for making (e)-7-(4-((5-((2-chlorobenzylidene)amino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
[patent_app_type] => utility
[patent_app_number] => 18/434620
[patent_app_country] => US
[patent_app_date] => 2024-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3778
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18434620
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/434620 | Process for making (e)-7-(4-((5-((2-chlorobenzylidene)amino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | Feb 5, 2024 | Issued |
Array
(
[id] => 19432452
[patent_doc_number] => 20240300950
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL][PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL[METHYL]-2-PYRIDINECARBOXAMIDE AS A COVALENT INHIBITOR OF MENIN-MLL INTERACTION
[patent_app_type] => utility
[patent_app_number] => 18/427226
[patent_app_country] => US
[patent_app_date] => 2024-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49582
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427226
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/427226 | Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide] | Jan 29, 2024 | Issued |
Array
(
[id] => 19345165
[patent_doc_number] => 20240254128
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
[patent_app_type] => utility
[patent_app_number] => 18/423972
[patent_app_country] => US
[patent_app_date] => 2024-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38174
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423972
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/423972 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | Jan 25, 2024 | Abandoned |
Array
(
[id] => 20120438
[patent_doc_number] => 20250235469
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-24
[patent_title] => Synergistic combinations of Finasteride, Dutasteride, and Minoxidil
[patent_app_type] => utility
[patent_app_number] => 18/421107
[patent_app_country] => US
[patent_app_date] => 2024-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18421107
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/421107 | Synergistic combinations of Finasteride, Dutasteride, and Minoxidil | Jan 23, 2024 | Pending |
Array
(
[id] => 20270795
[patent_doc_number] => 12440560
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-14
[patent_title] => Substituted pyrimidines as vaccine adjuvants
[patent_app_type] => utility
[patent_app_number] => 18/420017
[patent_app_country] => US
[patent_app_date] => 2024-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 8004
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420017
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/420017 | Substituted pyrimidines as vaccine adjuvants | Jan 22, 2024 | Issued |
Array
(
[id] => 19528126
[patent_doc_number] => 20240352028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C
[patent_app_type] => utility
[patent_app_number] => 18/416739
[patent_app_country] => US
[patent_app_date] => 2024-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416739
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/416739 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | Jan 17, 2024 | Pending |
Array
(
[id] => 20341865
[patent_doc_number] => 12465580
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-11
[patent_title] => Substituted fatty acids for treating non-alcoholic steatohepatitis
[patent_app_type] => utility
[patent_app_number] => 18/414988
[patent_app_country] => US
[patent_app_date] => 2024-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 6159
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414988
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/414988 | Substituted fatty acids for treating non-alcoholic steatohepatitis | Jan 16, 2024 | Issued |
Array
(
[id] => 19418357
[patent_doc_number] => 20240294480
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO
[patent_app_type] => utility
[patent_app_number] => 18/414456
[patent_app_country] => US
[patent_app_date] => 2024-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 336
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414456
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/414456 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Jan 15, 2024 | Abandoned |
Array
(
[id] => 19521068
[patent_doc_number] => 12122775
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-10-22
[patent_title] => Substituted pyrido[4,3-e]pyrrolo[1,2-a]pyrazines as CK2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/413246
[patent_app_country] => US
[patent_app_date] => 2024-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9215
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413246
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/413246 | Substituted pyrido[4,3-e]pyrrolo[1,2-a]pyrazines as CK2 inhibitors | Jan 15, 2024 | Issued |
Array
(
[id] => 19631060
[patent_doc_number] => 20240409509
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/413817
[patent_app_country] => US
[patent_app_date] => 2024-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32651
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413817
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/413817 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | Jan 15, 2024 | Pending |
Array
(
[id] => 19637411
[patent_doc_number] => 12168007
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-12-17
[patent_title] => Substituted piperazines as dopamine D3/D2 receptor modulators
[patent_app_type] => utility
[patent_app_number] => 18/409478
[patent_app_country] => US
[patent_app_date] => 2024-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8538
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18409478
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/409478 | Substituted piperazines as dopamine D3/D2 receptor modulators | Jan 9, 2024 | Issued |